- Mechanism
- Stimulates glucose-dependent insulin release and delays gastric emptying
- Typical research dose
- 0.75 mg to 4.5 mg weekly subcutaneous
- Route
- subcutaneous
- Half-life
- ~5 days
- Legal status
- FDA Approved
Overview
Dulaglutide, widely known by its brand name Trulicity, is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. This synthetic Dulaglutide peptide functions by mimicking natural incretin hormones to stimulate insulin secretion and suppress glucagon release in a glucose-dependent manner. It is highly valued in clinical settings for improving glycemic control in adults with type 2 diabetes while offering secondary benefits like delayed gastric emptying and appetite suppression. As a once-weekly subcutaneous injection, it provides a convenient and effective therapeutic option for long-term metabolic disease management.
Potential Benefits
- Enhanced Glycemic Control: Dulaglutide significantly lowers HbA1c levels by stimulating glucose-dependent insulin secretion and reducing inappropriate glucagon output.
- Targeted Weight Management: By delaying gastric emptying and promoting satiety in the brain, Dulaglutide benefits patients by facilitating moderate, sustained weight loss.
- Cardiovascular Risk Reduction: Clinical trials demonstrate that the peptide reduces the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes and established heart disease.
- Beta-Cell Function Preservation: Research indicates that GLP-1 receptor agonists may help protect and preserve pancreatic beta-cell function over time by reducing cellular stress.
- Improved Fasting Glucose: The extended half-life of this peptide ensures steady-state concentrations that effectively lower both fasting and postprandial blood glucose levels.
Side Effects
Common side effects:
- Nausea and vomiting
- Diarrhea or constipation
- Abdominal pain and cramping
- Decreased appetite
- Injection site reactions
Rare or serious side effects:
- Pancreatitis
- Thyroid C-cell tumors (black box warning)
- Severe hypoglycemia (when combined with insulin)
- Acute kidney injury
Dulaglutide is FDA-approved but should only be used under medical supervision. Consult a qualified healthcare provider before use.
Mechanism of Action
GLP-1 Receptor Activation is the primary mechanism by which the Dulaglutide peptide exerts its metabolic effects. The molecule binds to and activates the GLP-1 receptor on pancreatic beta cells, triggering an intracellular signaling cascade involving cyclic AMP (cAMP). This cascade leads to the glucose-dependent release of insulin, ensuring that blood sugar levels are lowered only when elevated to minimize hypoglycemia risk.
Systemic Metabolic Regulation extends beyond the pancreas, as the peptide also influences the gastrointestinal tract and central nervous system. It slows gastric emptying to blunt post-meal blood glucose spikes and crosses the blood-brain barrier to interact with hypothalamic receptors. This dual action effectively suppresses appetite, contributing to the weight loss often observed during therapy.
Origin & History
Discovery and Development of Dulaglutide was spearheaded by Eli Lilly and Company to address the need for a longer-acting GLP-1 receptor agonist. Researchers engineered the molecule by fusing two modified GLP-1 analog molecules to a human IgG4 Fc fragment, which protects the peptide from rapid degradation by the DPP-4 enzyme. This structural innovation significantly extended its half-life, allowing for a once-weekly dosing schedule that drastically improved patient compliance.
FDA Approval and Clinical Milestones were officially reached in September 2014 under the brand name Trulicity. Initially approved as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes, its indications were expanded in 2020 to include the reduction of major adverse cardiovascular events. Today, it remains a cornerstone therapy in metabolic and endocrine medicine.